Condition: Mitral Regurgitation · Sponsor: HighLife SAS
Study to evaluate the feasibility, safety and performance of the HighLife trans-septal Transcatheter Mitral Valve in patients with moderate-severe and severe mitral regurgitation who are at high risk for surgical treatment.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Tucson Medical Center | Tucson, Arizona, United States | Recruiting |
| Los Robles Regional Medical Center | Los Angeles, California, United States | Recruiting |
| Piedmont Heart | Atlanta, Georgia, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Minneapolis Heart | Minneapolis, Minnesota, United States | Recruiting |
| Montefiore Medical Center | New York, New York, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Terminated |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
| Chippenham Hospital Richmond | Richmond, Virginia, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04029337